SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Efficacy and Cost-effectiveness of Autologous Bone Marrow Transplantation in Metastatic Breast Cancer
4 references·8 citing·45 second hop
Efficacy and Cost-effectiveness of Autologous Bone Marrow Transplantation in Metastatic Breast Cancer (1992)Efficacy and Cost-effectiveness of Autolo…Setting Health Care Priorities in Oregon (1991)Setting Health Care Prioritie…Efficacy and Cost Effectiveness of Adjuvant Chemotherapy in Women with Node-Negative Breast Cancer (1991)Efficacy and Cost Effectivene…A Clinician's Guide to Cost-Effectiveness Analysis (1990)A Clinician's Guide to Cost-E…The Markov Process in Medical Prognosis (1983)The Markov Process in Medical…Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer (2015)Cost-Effectiveness of Pertuzu…A Cost-Effectiveness Analysis of Adjuvant Trastuzumab Regimens in Early HER2/neu–Positive Breast Cancer (2007)A Cost-Effectiveness Analysis…Cost-Effectiveness versus Cost–Utility Analysis of Interventions for Cancer: Does Adjusting for Health-Related Quality of Life Really Matter? (2004)Cost-Effectiveness versus Cos…A Cost-Utility Analysis of Second-Line Chemotherapy in Metastatic Breast Cancer (1996)A Cost-Utility Analysis of Se…Sensitivity analysis in economic evaluation: A review of published studies (1995)Sensitivity analysis in econo…Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer. (1995)Economic evaluation of a rand…Cost-effectiveness of captopril therapy after myocardial infarction (1995)Cost-effectiveness of captopr…Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy outcomes. (1993)Should the elderly receive ch…Reporting results of cancer treatment (1981)Markov Models in Medical Decision Making (1993)Current Trends in the Use of Pharmacoeconomics and Outcomes Research in Europe (1999)Cost Effectiveness of Treatment Options in Advanced Breast Cancer in the UK (2001)Preference and Urgency (1975)Foundations of Cost-Effectiveness Analysis for Health and Medical Practices (1977)A general health policy model: update and applications. (1988)A review of the use of health status measures in economic evaluation. (1999)Incorporating societal concerns for fairness in numerical valuations of health programmes (1999)Cost-Effectiveness Analysis and the Consistency of Decision Making (2001)Measurement of health state utilities for economic appraisal (1986)How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. (1992)Cost-effectiveness of Routine Coronary Angiography After Acute Myocardial Infarction (1996)Use of Quality Adjusted Life Years and Life Years Gained as Benchmarks in Economic Evaluations: A Critical Appraisal (2003)Cost-Effectiveness of Eplerenone Compared With Placebo in Patients With Myocardial Infarction Complicated by Left Ventricular Dysfunction and Heart Failure (2005)Optimistic Biases About Personal Risks (1989)Assessment of quality of life in clinical trials (1991)Cost-utility in practice: A policy maker's guide to the state of the art (1992)HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis (2004)Clinical decision analysis (2005)Clinical Decision Analysis (1980)Methods for the economic evaluation of health care programmes (1987)Costs, effects and C/E‐ratios alongside a clinical trial (1994)Advances in Cost-Effectiveness Analysis of Health Interventions (1999)Economic evaluation of communicable disease interventions in developing countries: a critical review of the published literature (2000)Sensitivity Analysis in Cost-Effectiveness Studies (2011)The Distinction Between Cost and Charges (1982)Cost-Effectiveness and Cost-Benefit Analyses in the Medical Literature (1992)Psychometric considerations in evaluating health-related quality of life measures (1993)Methods for the Economic Evaluation of Health Care Programmes (2005)Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold (2008)Cost-Effectiveness in Health and Medicine (1996)Projections of the Cost of Cancer Care in the United States: 2010-2020 (2011)Cost-Effectiveness in Health and Medicine (2016)The Beaver Dam Health Outcomes study (1993)Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer (2007)Economic Evaluations of Medical Care Interventions for Cancer Patients: How, Why, and What Does it Mean? (2008)XXIV. On the nature of the function expressive of the law of human mortality, and on a new mode of determining the value of life contingencies. In a letter to Francis Baily, Esq. F. R. S. &c (1825)A Population Study. (1975)A convenient approximation of life expectancy (the “DEALE”) (1982)Decision Making in Health and Medicine: Integrating Evidence and Values (2001)State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3 (2012)Benefit and Cost Analysis in Geriatric Care (1984)A New Decision Model for Cost-Utility Comparisons of Chemotherapy in Recurrent Metastatic Breast Cancer (1996)Cancer in Low- and Middle-Income Countries: An Economic Overview (2015)
this work references cited by second hop

References

  • 1983The Markov Process in Medical Prognosis957 cited
  • 1990A Clinician's Guide to Cost-Effectiveness Analysis707 cited
  • 1991Setting Health Care Priorities in Oregon441 cited
  • 1991Efficacy and Cost Effectiveness of Adjuvant Chemotherapy in Women with Node-Negative Breast Cancer237 cited

Cited by

  • 1995Cost-effectiveness of captopril therapy after myocardial infarction128 cited
  • 2007A Cost-Effectiveness Analysis of Adjuvant Trastuzumab Regimens in Early HER2/neu–Positive Breast Cancer119 cited
  • 1995Sensitivity analysis in economic evaluation: A review of published studies119 cited
  • 2015Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer115 cited
  • 1993Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy outcomes.102 cited
  • 1996A Cost-Utility Analysis of Second-Line Chemotherapy in Metastatic Breast Cancer93 cited
  • 1995Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer.87 cited
  • 2004Cost-Effectiveness versus Cost–Utility Analysis of Interventions for Cancer: Does Adjusting for Health-Related Quality of Life Really Matter?76 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work